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Abstract: The past decade revealed that cell identity changes, such as dedifferentiation or transdif-
ferentiation, accompany the insulin-producing β-cell decay in most diabetes conditions. Mapping
and controlling the mechanisms governing these processes is, thus, extremely valuable for managing
the disease progression. Extracellular glucose is known to influence cell identity by impacting the
redox balance. Here, we use global proteomics and pathway analysis to map the response of differ-
entiating human pancreatic progenitors to chronically increased in vitro glucose levels. We show
that exogenous high glucose levels impact different protein subsets in a concentration-dependent
manner. In contrast, regardless of concentration, glucose elicits an antipodal effect on the proteome
landscape, inducing both beneficial and detrimental changes in regard to achieving the desired islet
cell fingerprint. Furthermore, we identified that only a subgroup of these effects and pathways are
regulated by changes in redox balance. Our study highlights a complex effect of exogenous glucose
on differentiating pancreas progenitors characterized by a distinct proteome signature.
Keywords: cell identity; cell fate; in vitro differentiation; pancreatic endocrine progenitors; hiPSC;
signaling pathway analyses; exogenous glucose; proteomics
1. Introduction
A shared feature of most diabetes disorders is the ultimate loss of functional insulin-
producing pancreatic β-cells. This apparent common denominator hides an unexpected
level of complexity: loss does not necessarily equal death. Although death might represent
the final outcome, current research suggests a much more complex situation [1], where
β-cells display a variety of initial responses which prevent or precede permanent loss, such
as dedifferentiation [2,3] or transdifferentiation [4–7]. Thus, understanding the mechanisms
governing identity maintenance in the pancreatic islet will allow for impeding or maybe
even reversing the decay process.
Previous studies on a wide range of cell types indicated extracellular glucose con-
centrations as being a key contributor to cell fate decisions [8]. The impact of glucose
levels is mainly attained through modulating the redox balance of the exposed tissue or
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cell type. The resultant reactive oxygen species act as secondary messengers improving
differentiation and tissue remodeling. Nevertheless, if the redox disequilibrium is impor-
tant or persistent, the oxidative stress will cause cellular damage and will ultimately result
in apoptosis of the affected cell [8,9]. Consequently, the cellular antioxidant and repair
mechanisms are of utmost importance for cell functionality and identity.
Pancreatic islet cells are no exception, with studies showing that short exposure to
high glucose concentrations is able to potentiate β-cell function [10,11], while the physio-
logical glucose concentration is critical for β-cell identity maintenance (reviewed in [12]).
In contrast, long-term high glucose concentrations were clearly linked to β-cell dediffer-
entiation and dysfunction in different rodent models [2,12–14], cell lines [15] and human
islets in vitro [16,17].
Generating islet cells and especially β-cells through guided in vitro differentiation
from human-induced pluripotent stem cell (hiPSC) or embryonic stem cell (ESC) sources
has a huge therapeutic potential [18–21], besides providing a context for demultiplexing
the factors involved in β-cell fate acquisition, maintenance and pathology [22]. In the
current differentiation protocols, hiPSCs/ESCs are differentiated in a stepwise manner,
mimicking the natural stages of β-cell development [23–25]. Of importance, most published
protocols incorporate a glucose concentration switch during the last differentiation stages
(initiated at the pancreas progenitor stage), involving a raise from physiological (10 mM) to
elevated (20 mM) glucose levels [24,26–28]. Consequently, the in vitro generated pancreatic
progenitors gradually mature in a non-physiological hyperglycemic environment, which
is, however, important for their differentiation.
We recently assessed the effect of short-term and long-term in vivo elevated hyper-
glycemia on encapsulated and xenotransplanted hiPSC-derived pancreatic progenitors. Of
note, encapsulation increased the yield of islet cell types, without, however, improving cell
identity selection [29], a parameter resolved by xenotransplantation into normoglycemic
animals [30]. This beneficial effect on β-cell identity is lost when cells are transplanted into
overly diabetic hosts due to hyperglycemia-induced oxidative stress, which results in the
accumulation of immature cells and, following prolonged exposure, apoptosis [31]. It is,
however, still unclear if exposure to elevated glucose concentrations elicit the same effects
in vitro during the last stages of guided differentiation. Here, we used global proteomics to
map the proteome landscape changes of differentiating pancreas progenitors in response
to increased glucose concentrations in vitro. We show that, according to concentration,
elevated exogenous glucose levels mobilize different metabolic and developmental re-
sponses. Moreover, by performing a comparative pathway analysis on glucose-, oxidant-
and antioxidant-treated samples, we show that these effects are only partially relayed by
changes in the redox balance and energy metabolism.
2. Results
2.1. High Glucose Concentrations Dysregulate Key Factors with Role in Pancreatic Islet Cells
Development
In order to characterize the effects of in vitro hyperglycemia on the proteome finger-
print of differentiating islet cells, we exposed hiPSC-derived pancreatic progenitors to
highly elevated glucose concentrations during the last two stages of differentiation. For
hiPSC differentiation, we employed one of the most reliable and widely used protocols,
elaborated by [24], which consists of seven differentiation steps over a period of one month.
Of note, this protocol involves, by default, exposing the cells to a non-physiological glucose
concentration (20 mM) from the pancreatic progenitor stage onwards (2 weeks, from stages
5 to 7) [24].
Briefly, three distinct hiPSC colonies were differentiated during three distinct differen-
tiating rounds as previously described [32,33]. Starting at the pancreatic progenitor stage
(stage 5), cells were exposed to the appropriate differentiation cocktail containing either
the protocol “standard” 20 mM glucose (standardly elevated) or higher glucose levels of 25
(mildly increased) and 30 mM (highly increased) (Figure 1a). Of note, the term “standard”
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will be further used to designate the standard, but not physiological, concentration required
in the differentiation protocol and does not refer to “standard physiological conditions”.
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Cell viability was found to be above 85% for all samples (Figure 1b). Subsequently, the
different glycemic conditions as well as native human islets isolated from deceased donors
were compared using global proteomics (tandem mass tag (TMT) 11-plex proteomics). The
assay revealed 8858 unique proteins, with 7965 being detected in all conditions.
The hierarchical clustering of the averaged TMT ratios of 4947 differentially expressed
proteins between stage 7 cells and human islets revealed the highest glucose concen-
tration to have the strongest impact on the proteome landscape (Figure 1c), with the
samples exposed to 30 mM glucose clustering farther away from the standard control
(20 mM glucose).
We further interrogated the abundance of the main islet-specific hormones in the
different conditions analyzed. There was no significant difference in the hormone levels be-
tween the samples differentiated by various glucose concentrations (Figure 1d,e). Markers
with a key role in islet cells’ development such as GATA4 or chromogranin A (CHGA) were
significantly dysregulated in the 25-mM samples (Figure 1f), while Paired Box 6 (PAX6)
was impacted at the higher 30-mM concentration (Figure 1f), similar to the β-cell maturity
maker PCSK1 (Figure 1g). Of note, the samples exposed to the higher glucose concentration
displayed a high overall inter-replicon variation, which could account for fewer markers
passing the significance threshold in this condition. These results suggest that increased
glucose concentrations impact islet cell fate acquisition, although without a significant
impact on hormone expression, besides glucagon (GCG).
2.2. Mildly Increased Glucose Levels Impact the Growth and Developmental Profile of the In Vitro
Differentiating Cells
To comprehensively characterize the effect of mildly increased glucose concentra-
tions on differentiating islet cells, we performed a pathway analysis on the differen-
tially expressed proteins (DEPs) between the cells exposed to 25 mM glucose and their
controls (20 mM glucose). We detected 370 proteins being differentially expressed
(Supplemental Table S1) in 25-mM-exposed samples as compared to the control, with
~2/3 (68.65%, 254/370) being downregulated and ~1/3 (31.35%, 116/370) being upregu-
lated (Figure 2a). Moreover, just one of 14 previously characterized β-cell constitutively
expressed proteins (Vesicle Associated Membrane Protein 2, VAMP2) [34] was found differ-
entially expressed (Supplemental Table S2). Ingenuity Pathway Analysis software (IPA)
revealed the regulation of pathways involved in cell cycle, energy metabolism, neurogene-
sis and development, amongst others (Figure 2b).
Briefly, pathways involved in neuro- and neuritogenesis were predicted as inhibited,
with several being found in the top regulated pathways of the analyzed proteome land-
scape (Figure 2b). These results were corroborated by the disease and function analysis,
which inferred the decrease in the neurodevelopment-related processes with a high level of
confidence. Moreover, the dysregulation of this subset of proteins was the most representa-
tive for the global proteome landscape (Supplementary Figure S1a). These results suggest
that mildly increased glucose levels inhibit pathways involved in neuronal development.
Furthermore, signaling involved in cell cycle check-points’ regulation was inferred as
inhibited, while signaling related to mitotic progression was predicted as activated, sug-
gesting dysregulated proliferation in 25-mM-exposed samples (Figure 2b, purple frames).
In addition, oxidative phosphorylation signaling (OXPHOS, Figure 2b, black frame) was
inhibited when compared to control samples, indicating a potential alteration of the energy
metabolism. Last, the canonical Wnt pathway was indicated as activated in 25-mM-exposed
samples, suggesting its potential impact on the differentiation potential.
Accordingly, the top-rated networks characterizing the analyzed regulatory landscape
consisted of proteins involved in Cellular Growth and Proliferation, Cancer and Embryonic
and Tissue Development (Figure 2c), further supporting the above conclusion of the impact
of exposure to 25 mM glucose on proliferative, energy and developmental processes.
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At single-protein resolution, the pan-endocrine marker chromogranin A (CHGA),
GCG hormone and the PAX6 transcription factor were dysregulated, with the first two
being the top downregulated proteins of the analyzed landscape (Figure 2d). Interestingly,
several key factors involved in islet and β-cell development were significantly upregulated
(Figure 2e) following mildly elevated glucose exposure, albeit without an obvious impact
on hormone abundance, with the exception of glucagon. Unfortunately, due to the detection
limitation of the techniques, we were unable to detect lowly expressed islet cell markers,
such as pancreatic and duodenal homeobox 1 (PDX1), NKX6.1 (NK6 Homeobox 1), ARX
(Aristaless Related Homeobox) or MAFA (musculoaponeurotic fibrosarcoma oncogene
homolog). Beside key islet cell markers, WNT1 and WNT3 ligands were also found
upregulated (Figure 2f), suggesting them as main activators of the canonical Wnt pathway
in this context.
Overall, these results suggest an impact of the mildly elevated glucose levels on the
in vitro proliferation potential and the differentiation program of the pancreatic progenitors,
arguable through a Wnt-based mechanism.
2.3. Mildly Elevated Glucose Level Elicits both Beneficial and Detrimental Effects on the Islet Cell
Signature of the Differentiating Cells
The above analysis provides insights into the general effects of mildly elevated glucose
levels but fails to address their positive or negative impact on islet cell differentiation.
Thus, to address which of the identified regulations are promoting an improved islet-like
signature or, in contrast, inhibit it, we introduced islet samples for normalization. This
allowed us to discriminate between the DEPs that change their abundance profiles in
response to exposure to 25 mM glucose towards the levels detected in the islets (islet-
heading regulation, Figure 2g) and the ones exhibiting the opposite regulation (islet-
antagonizing regulation, Figure 2h). A total of 186 DEPs (fold change (FC) ≥ 1.5, p < 0.05)
exhibited an islet-heading regulation, with the vast majority (77.96%, 145/181) being
downregulated towards the islet abundance levels (Figure 2g). In contrast, 164 DEPs
displayed (FC ≥ 1.5, p < 0.05) an islet-antagonizing regulation, being regulated away from
the abundance levels normally detected in bona fide islets (Figure 2h).
The pathway comparison of these two subsets revealed the involvement of the proteins
exhibiting islet-heading regulation in inhibiting pluripotency and growth, modulating pro-
liferation and promoting endocrine system development and energy expenditure (Figure 2i,
Supplementary Figure S1b). Of note, most of the top pathways were almost exclusively
driven by the proteins belonging of this subset (i.e., proteins exhibiting islet-headed regula-
tion, Figure 2i).
In contrast, the proteins displaying islet-antagonizing regulation are controlling de-
velopmental processes as well as energy and lipid metabolism (Figure 2j). Interestingly,
key proteins driving the canonical Wnt signaling activation were included in this subset
(selected examples in Figure 2k), suggesting an adverse impact of its activation on islet
cell fate acquisition. Along the same line, the regulation away from islet abundance levels
of the proteins controlling energy (complex I, Figure 2j,l, Supplementary Figure S1c) and
lipid metabolism (Figure 2j, l, Supplementary Figure S1c) might also indicate that lipid
synthesis inhibition and OXPHOS lowering represent harmful effects of the exposure to
mildly elevated glucose concentrations.
As expected, GCG and CHGA were included in the islet-antagonizing effect due
to their observed downregulation away from the islet abundance level in response to
increased glucose levels (Figure 2m). Of interest, the HNF4A (Hepatocyte Nuclear Factor 4
Alpha) master regulator was significantly upregulated, arguably suggesting a potential
indirect effect on glucagon levels (Figure 2n).
Taken together, these results suggest that mildly elevated glucose promotes differentia-
tion and modulates proliferation towards islet-like regulation but impedes the achievement
of a true islet profile by interfering with the energy and lipid metabolism as well as modify-
ing the hormone expression patterns. Arguably, these effects are not entirely passive, as
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increased glucose levels negatively regulate signaling pathways with key developmental
roles in differentiation.
2.4. Pathway Analysis Reveals a Largely Different Protein Regulation in Response to Highly
Increased Glucose Levels
We further addressed whether the above proteome landscape regulation is retained
when pancreatic progenitors are differentiated at higher glucose (30 mM) concentrations
(Figure 3a). We identified 312 proteins being differentially expressed (FC ≥ 1.5, p < 0.05)
between 30-mM-exposed samples and the control (20 mM glucose), with the vast majority
of proteins being downregulated (90.71%, 283/312). The pathway analysis revealed the
inhibition of canonical Wnt signaling in the top regulated pathways characterizing the
global proteome landscape (Figure 3b), in stark contrast with its regulation following
mildly elevated glucose (Figures 2b and 3b). Along the same line, the PCP (planar cell
polarity) pathway (non-canonical Wnt signaling) was also predicted as downregulated
(Figure 3b, top 3), suggesting a global inhibition of Wnt signaling by the 30-mM glucose
concentration. As expected, critical ligands and regulators of the canonical Wnt and PCP
pathway, WNT5A and WNT7A, respectively, were significantly downregulated (Figure 3c).
In agreement with the unusually high number of downregulated DEPs, EIF2 (Eu-
karyotic Initiation Factor 2) signaling (inhibited) and sumoylation signaling (activated)
were identified in the top five canonical pathways, indicating that exposure to 30 mM
glucose negatively impacts protein synthesis and increases their turnover (Figure 3b).
Accordingly, the top ranked network consisted of proteins involved in protein synthesis
regulation, while the second and third top networks comprised of proteins involved in
developmental processes (Figure 3d). At single-protein levels, key developmental tran-
scription factors such as PAX6, MEIS2 and SOX9 and negative regulators such as SUFU
were found significantly downregulated (Figure 3c).
Similar to the mildly elevated glucose concentration effect, the synaptogenesis sig-
naling pathway was inferred as inhibited (Figure 3b), suggesting an inhibitory action of
elevated glucose on the neurogenesis pathways regardless of concentration (25 or 30 mM).
Of note, the tox analysis of the 30-mM-exposed samples indicated interference with
antioxidant mechanisms, such as the NRF2 (nuclear factor erythroid 2–related factor 2)-
mediated oxidative stress response, an indicator of potential redox imbalance (Figure 3e).
Overall, these results suggest that the two distinct glucose concentrations elicit fairly
different effects on differentiating pancreatic endocrine cells.
2.5. Highly Increased Glucose Level Modulates the Canonical Wnt Signaling towards Native Islet
Regulation, while Negatively Impacting Energy Metabolism and Protein Synthesis
Following a similar strategy as above, we identified the subsets of proteins following
an islet-heading regulatory pattern after 30-mM glucose exposure (Figure 3f). A total of
178 DEPs fulfilled this requirement, most being downregulated towards islet abundance
levels (Supplemental Table S1). The pathway analysis of this subset revealed, in the top
canonical pathway, canonical Wnt signaling inhibition (Figure 3g). In accordance, based
on the observed regulatory landscape, the analysis predicted β-catenin as an upstream
regulator. Accordingly, both WNT5A and WNT7A ligands as well as the SOX9 transcription
regulator displayed an islet-heading regulation (Figure 3h). Of note, based on previous
studies, 30 mM glucose is expected to elicit toxic effects on mature cells and tissues.
Furthermore, decreases in a wide range of processes related to neuronal development
were indicated in the top disease and function (Supplementary Figure S2a), suggesting that
inhibition of neurogenesis mechanisms by elevated glycemia levels potentially promotes
islet cell fate. Moreover, the global integration of all pathway analysis levels is suggestive
of a potential link between the inactivation of the canonical Wnt signaling pathway and
decreased neurogenesis (Supplementary Figure S2b). Nevertheless, further experimental
validation will be required to properly validate this observation.
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Figure 3. Pathway analysis of 30-mM glucose concentration effect. (a) Analysis workflow depicting the comparison
employed. (b) Top canonical pathways with predicted regulation characterizing the 30-mM glucose condition. (c) Graphs
of the observed downregulated WNT5A and WNT5B ligands and PAX6, MEIS2 (Meis homeobox 2), SUFU (suppressor
of fused protein) and SOX9 (SRY-Box Transcription Factor 9) in the 30 mM glucose condition. (d) Top networks and
(e) top tox list characterizing the proteome landscape of the 30 mM glucose condition. (f) Scheme depicting the selection
strategy and number of proteins displaying a dynamic of regulations compatible with an islet-heading regulatory pattern
in response to 30 mM glucose. (g) Top 3 canonical pathways and the network representation of one of the top predicted
upstream regulators’ (Catenin Beta 1, CTNNB1) target molecules. (h) Graphs of WNT5A, WNT7A and SOX9 following an
islet-heading regulation pattern. (i) Scheme depicting the selection strategy and number of proteins displaying a dynamic
of regulations compatible with an islet-antagonizing regulatory pattern in response to 30 mM glucose. (j) Top 5 canonical
pathways characterizing the subgroup of proteins displaying islet-antagonizing regulation. (k) Graphs of the β-cell markers
PCSK1 and KDM6A (Lysine Demethylase 6A) presenting an islet-antagonizing regulation pattern. (l) IPA-generated
network representations of selected dataset differentially expressed proteins (DEPs) characterizing the corresponding top
disease and function processes. * p < 0.05, ** p < 0.01.
In contrast, a subset of 117 DEPs displayed an islet-antagonizing regulation following
exposure to high concentrations of glucose (Figure 3i). Interestingly, the pathway analysis
showed inactivation of the EIF2 pathway (z-value = −2) as the second top canonical path-
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way (Figure 3j). Consistently, the network analysis indicated proteins involved in protein
synthesis regulation in the top ranked network (Supplementary Figure S2c), suggesting the
protein subset’s involvement in inhibiting protein synthesis. Moreover, integrin-based sig-
naling (Ras Homolog Family Member A (RhoA) signaling, integrin signaling (2.25 × 10−2),
actin cytoskeleton signaling (2.42 × 10−2)) and synaptogenesis signaling inhibition, as well
as PCP pathways, also define the regulatory group (Figure 3j, Supplementary Figure S2c).
These data promote the importance of cytoskeleton remodeling and non-canonical Wnt
signaling activation during the last stages of differentiation.
At the single-protein level, both the neuroendocrine convertase PCSK1 and the key
β-cell fate methylase KDM6A display an islet-antagonistic regulation, pointing towards
differentiation and maturation problems of the islet cells as a consequence of high glucose
exposure (Figure 3k).
Of interest, the disease and function analysis also indicated the increased production
of reactive oxygen species in this context (Figure 3l), suggestive of potential oxidative
stress damage.
2.6. The Differential Proteome Landscape between Mildly and Highly Increased Glucose Is
Characterized by Reduced Protein Synthesis and Low Antioxidant Activity
To further characterize the effect differences between the two glucose exposure set-
tings, we directly compared the 30- and 25-mM glucose samples. A total of 314 DEPs
(FC ≥ 1.5, p < 0.05) were found to be differentially regulated (Supplemental Table S1), with
most of them presenting a downregulated pattern (Figure 4a). Moreover, just two out of
14 previously characterized β-cell constitutively expressed proteins (DDX17 (DEAD-Box
Helicase 17), PPIB (Peptidylprolyl Isomerase B)) [35,36] were found differentially expressed
(Supplemental Table S2). The pathway analyses of the overall proteome landscape pointed
towards the deregulation of signaling involved in protein synthesis, antioxidant activity
and cytoskeleton organization. As such, the EIF2 signaling pathway was detected as the
top canonical pathway characterizing the analyzed landscape and inferred as inhibited
(Figure 4b, blue rectangle). Consistently, the top rated network consisted of proteins in-
volved in protein synthesis, with all but one being significantly downregulated in the
samples exposed to 30 mM glucose, indicating that the highly elevated glucose concentra-
tion inhibits protein synthesis (Figure 4c).
Of note, one of the main detox pathways, the NRF2-mediated oxidative stress re-
sponse (top two), was also predicted to be downregulated as compared to the 25-mM
glucose condition, suggesting a lower capacity of the 30-mM-exposed cells to maintain
the redox balance. This conclusion is also corroborated by the upstream analysis, which
indicated NFE2L2 (Nuclear Factor, Erythroid 2 Like 2, NRF2) as one of the top inhibited
upstream regulators of the analyzed proteome landscape (Figure 4d). The overview of
the global proteome landscape also indicated a clear interplay between the inhibition
of (1) NFE2L2/NRF2 (antioxidant activity), (2) β-catenin (canonical Wnt pathway) and
(3) EIF2 signaling and EIF4 (protein synthesis) as the main fingerprint of the analyzed
subset (Figure 4e, red arrows).
To validate this finding, we checked NRF2 activity by immunofluorescence and found
a clear difference in the expression patterns between the two elevated glucose levels
(Figure 4f). Following exposure to 25 mM ectopic glucose, the cells presented a dual
cytoplasmic (inactive) and nuclear (active) pattern of NRF2 staining. In contrast, at 30 mM
glucose, the pattern was exclusively cytoplasmic, indicating a lower antioxidant activity, in
accordance with the pathway analysis.




Figure 4. Direct comparison analysis between the proteome landscape of 30 and 25 mM glucose conditions. (a) Analysis
workflow depicting the comparison employed. (b) Top canonical pathways with predicted regulation characterizing
the differentially expressed protein landscape between 30 and 25 mM glucose conditions. (c) Selected top 2 organic
networks displaying the observed downregulation of proteins involved in protein synthesis. (d) Top predicted activated
upstream transcription regulators and the NFE2L2 (NRF2) target molecules observed regulated in the analyzed DEPs
dataset. (e) IPA-generated global integration of all pathway analysis levels characterizing the differentially expressed
protein landscape between 30 and 25 mM glucose conditions. (f) Confocal imaging of representative NRF2+ cells (yellow)
in 25- and 30-mM-treated samples (Scale bar: 25 µm; blue–DAPI). (g) Relative abundance levels of superoxide dismutase 1
(SOD1) and (h) G6PC2 (Glucose-6-Phosphatase Catalytic Subunit 2) proteins (one-way ANOVA with Tukey’s multiple
comparisons test, ** p < 0.01, **** p < 0.0001). Graphs are shown as mean ± SEM.
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In addition, superoxide dismutase 1 (SOD1), the main superoxide dismutase responsi-
ble for eliminating free superoxide radicals, was also significantly downregulated following
exposure to 30 mM glucose (Figure 4g), further indicating a reduced antioxidant activity
in these samples. Moreover, G6PC2, a key enzyme involved in glucose-6-phosphate hy-
drolysis in β-cells, was strongly downregulated after 30 mM glucose exposure, indicating
increased glycolysis pathway activity in this glucose condition (Figure 4h). This, connected
with antioxidant pathways in response to highly elevated glucose concentrations, suggests
a potential unbalanced redox equilibrium in these samples.
2.7. Elevated Glucose Concentrations and Redox Imbalance Prompt Similar but not
Overlapping Responses
To determine the contribution of a potential redox imbalance to the observed elevated
glucose-induced effects, we treated the differentiating cells with H2O2, a known exogenous
oxidative stress inducer, and analyzed their regulatory landscape using global TMT-plex
proteomics. To validate the H2O2 effect on the redox balance and antioxidant activity,
we checked the NRF2 expression level by immunofluorescence. We observed a clear
difference between H2O2 treatment and the control (20 mM), with the peroxide-treated
samples exhibiting a strong nuclear pattern on NRF2 (activated), while the control condition
displayed a clearly cytoplasmic NRF2 staining. This result suggests that the H2O2-treated
samples are compensating for the shift in redox balance by activating the antioxidant
mechanisms (Figure 5a).
A total of 542 DEPs (Supplemental Table S1) were filtered between the H2O2-treated
samples and the control untreated samples (Figure 5b). We further performed a pathway
analysis comparison to match the resultant regulatory profile against the ones characteriz-
ing the response to elevated glucose concentration exposure. This revealed that both the
H2O2-induced redox imbalance and the increased glucose level conditions are character-
ized by the decreased activity of the pathways involved in lipid metabolism (Figure 5c,
green bracket). Moreover, key pathways regulating development and growth presented
similar activity patterns (Figure 5c, orange bracket). In contrast, H2O2 exposure elicited an
opposite effect compared to glucose exposure on pathways involved in protein synthesis
(such as EIF2 signaling) or cellular remodeling and integrin signaling (RhoA and actin
cytoskeleton signaling) (Figure 5d). Of note, key pathways regulated by elevated glucose
concentrations, such as the canonical Wnt pathway, do not respond to H2O2 treatment,
suggesting that these are not modulated by glucose via changes in the energy metabolism
and redox balance, but rather through a different mechanism.
To validate the role of glucose-induced redox imbalance on modulating the subset
of pathways affected by both glucose concentration and H2O2, the differentiating cells
were treated with DMSO, a known antioxidant agent. Due to its antioxidant action, DMSO
was expected to promote an opposite regulatory pattern on this group of pathways, given
that they are indeed regulated by shifts in the redox balance. Indeed, assessing the NRF2
pattern by immunofluorescence revealed a strongly cytoplasmic staining, consistent with
low oxidative stress as anticipated following antioxidant treatment (Figure 5e).
A total of 885 DEPs (Supplemental Table S1) were filtered between the DMSO-treated
and control samples (Figure 5f) and the resultant landscape profile was compared against
the ones characterizing the H2O2-, 25-mM and 30-mM glucose-exposed samples.
With the exception of 3-phosphoinositide biosynthesis signaling, the pathways in-
volved in lipid metabolism were largely unaffected by the DMSO action (Figure 5g),
suggesting that these are either irresponsive to antioxidant stimulation or that H2O2 and
elevated glucose act through non-overlapping independent mechanisms.
In contrast, the DMSO treatment induced an opposite regulatory pattern in several
pathways modulated by both H2O2 and elevated glucose concentrations; nevertheless,
this effect seemed restricted to signaling involved in growth and development (such as
estrogen signaling pathway, senescence pathway and synaptogenesis signaling pathway,
Figure 5g).
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3. Discussion
H re, we ident fied the in vitro proteome landscape changes char cterizing hiPSC-
derived islet c lls exposed to elevated glucose levels from the pancreatic progen tor
stage. Interestingly, we discovered that the differentiating cells respond differently to
the two glucose concentrations used (25 or 30 mM) by modulating distinct pathways and
molecular targets.
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Admittedly, one of the limitations of this study is that it does not address whether
the effects of elevated glucose concentrations impact the protein expression levels or cell
populations’ size. Thus, we cannot properly establish if the increased glucose levels
interfere with the protein abundance or cell fate acquisition and maintenance. Although it
is beyond the scope of this study to unequivocally pinpoint the exact cellular mechanism,
based on the unchanged fraction of insulin-expressing cells and insulin levels, we can
speculate that, at least in the case of β-cell expressed markers, the probable scenario
involves changes in the expression rather than the number of positive expressing cells.
Nevertheless, this hypothesis should be rigorously addressed in future studies.
Of interest, the proteome landscape changes suggested both beneficial and detrimental
changes for the islet cells fingerprint. Our data indicated that only a small subset of the
identified regulatory landscape responds to changes in the redox balance, suggesting that
not all glucose effects are elicited via shifts in energy metabolism (Figure 6).
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One important aspect to consider is that the ifferentiating cells were exposed to
elevated glucose levels for a prolonged period of time. Indeed, the increase in glucose
concentration was performed starting with the pancreatic progenitor stage and it was
maintained up until the end of the protocol—thus, for a total of two weeks of exposure.
This is longer than the interval used in most other in vitro studies, which usually ranges
from 24 h to one week [11,37–39]. Thus, any acute or transient response to the increase in
glucose concentration would not be captured by the analysis, which focused only on the
long-lasting or incremental modifications. As such, the changes in the proteome landscape
represent the result of two weeks of sustained, chronically elevated, glucose exposure.
Nevertheless, it should be considered that we did not include an osmotic control, and
hence, it cannot be distinguished whether the observed effect was caused exclusively by
exposure to glucose or if the osmotic stress was also contributing factor.
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Furthermore, our analysis focused on the global proteome changes in response to
increased glucose levels and not on specific aspects of metabolism or development. This
setup allowed for discriminating between the beneficial and the detrimental effects of
exposure to elevated glucose levels. These antithetic effects were previously correlated
mostly with the length of glucose exposure or glucose concentration. Indeed, studies
showed that brief glucose treatments (≤24 h) could potentiate β-cell function [10,11], an
effect also noticed in response to physiological glucose stimulation values (10 mM) [12]. In
contrast, prolonged exposure or high glucose levels are detrimental for β-cell identity [40].
Nevertheless, our study shows that chronic high glucose exposure, besides the expected
detrimental effects, also affects several proteome subsets in an apparently beneficial manner,
one example being the inhibition of the canonical Wnt pathway. The importance of
canonical and non-canonical Wnt pathways for hiPSC differentiation was already indicated
by several studies [41]. A recent work [42] demonstrated the importance of canonical
Wnt pathway inhibition during endocrine differentiation of hESCs, a result in agreement
with our finding that inhibition of the Wnt/β-catenin pathway by highly elevated glucose
concentration (30 mM) is beneficial for the islet signature of the differentiating cells.
Our analysis further indicated the inhibition of the Wnt/PCP pathway as a detri-
mental effect of the same glucose concentration, in line with the findings of [43], which
uncovered that stimulating the non-canonical Wnt/PCP pathway by WNT5A upregulates
β-cell maturation makers and improves differentiation in P5 islet cells and pseudo-islets of
Min6 insulinoma cells. Of note, the regulation of the canonical Wnt/β-catenin pathway
illustrates the differential effect elicited by the two glucose concentrations, being detri-
mentally activated by exposure to 25 mM glucose and beneficially inhibited by treatment
with 30 mM. Nevertheless, the unequivocal link between canonical and non-canonical
Wnt signaling and glucose levels absolutely requires further experimental evidence, which
was not the object of this study. In addition, a direct comparison between the proteome
landscapes evoked by the two elevated glucose concentrations also revealed differences
in protein synthesis and antioxidant pathways, both inhibited in response to the highest
glucose concentration. The reduction in the antioxidant activity represents an interesting
result, as a large body of literature indicates [8,44,45] that glucose relays its effects by
impacting the redox balance and triggering a signaling cascade, which ultimately results in
an altered expression of key transcription regulators.
Of note, an additional aspect to consider here is glucotoxicity. The 30-mM concentra-
tion is a standard concentration at which glucose is expected to elicit deleterious effect on
target tissues or cells. However, the pathway analysis of our datasets did not reveal typical
signs of glucotoxicity, aside from the reduced levels of antioxidant activity, suggesting that
the immature differentiating pancreatic endocrine cells cope differently with increased
glucose concentrations than the mature ones.
Nevertheless, our comparative analysis revealed that only a small subset of pathways
are collectively regulated by oxidant, antioxidant and chronic elevated glucose levels. Of
interest, key developmental pathways regulating cell identity, such as the canonical and
non-canonical Wnt pathways, were not part of this subgroup, being regulated only by
chronic glucose exposure and not by peroxide or antioxidants (Figure 6). This observation
can signal a potential redox-independent action of glucose. Alternatively, considering
the length of elevated glucose exposure, the pathways refractory to redox imbalance can
simply represent a secondary wave of regulation in response to the sustained impairment
of energy metabolism. Moreover, it is possible that the immature energetic status of the
in vitro differentiating cells alters the standard response to oxidant and antioxidant agents.
In this respect, one important drawback of our approach is that the control sam-
ples differentiated using the standard protocol were already exposed to very high, non-
physiological glucose concentrations (20 mM). Thus, any impact on the redox balance
already intrinsic to the control samples would not be revealed by the differential expression
analysis. As such, the additional oxidative stress elicited by H2O2 treatment might have
a low impact on an already redox-imbalanced environment caused by chronic glucose
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exposure. Regardless of explanation, the impact of chronic high glucose concentrations on
key developmental pathways represents an important and exploitable finding.
Furthermore, the effects of the exogenous glucose exposure revealed here are in stark
contrast with our in vivo observations. hiPSC-derived pancreatic progenitors generated
by the same differentiation protocol and xenotransplanted into overtly hyperglycemic
mice presented dysregulation of energy metabolism and redox balance as main profile
changes [31]. This suggests that either the in vitro differentiating cells are too immature
to mount a proper energy metabolism response to glucose induction, or that exposure to
in vivo hyperglycemia is a more potent stimulus due to systemic action and interference
from other organs.
Overall, these results support a dual impact of elevated glucose levels that vary
according to concentration. Following chronic exposure, a large subset of the deregulated
proteome landscape does not seem to be regulated by redox imbalance, in contrast with
the in vivo exposure to hyperglycemia. Of interest, prolonged exposure to high glucose
concentrations modulates pathways with a key role in islet cell identity. Once more,
the targets and pathways revealed by this study require further experimental validation
before an absolute conclusion can be reached regarding their modulation by high glucose
concentrations.
4. Materials and Methods
4.1. Cell Sources and Ethical Statements
The experimental protocols reported in this study were approved by the Norwegian
Regional Committee of Medical and Health Research Ethics for the use of hiPSCs (REK
2010/2295) and human islets (REK 2011/426). All methods reported here were carried
out in accordance with the Helsinki Declaration. Informed consent was obtained from
healthy donor (for skin biopsies) or from the relatives (for organ donations). The hiPSC
lines characterized in this study were generated by episomal reprogramming using the
following vectors obtained from Addgene: OCT3/4 (#27077), L-MYC, LIN28 (#27080)
and SOX2, and KLF4 (#27078), as previously described by us [32,46]. The hiPS cells were
checked to be negative for mycoplasma by using a MycoAlert Mycoplasm Detection Kit
(Lonza, LT07-418) prior to differentiation. The pluripotency and differentiation potential
of these iPSCs were previously assessed [32,33,46]. Human islets were obtained from the
Juvenile Diabetes Research Foundation (JDRF) award 31-2008-416 (ECIT Islet for Basic
Research program) and isolated as previously described [47] from males/female 2/1 non-
diabetic brain dead donors with a mean age of 50 years (35–60 years) and a mean body
mass index (BMI) of 25.7 kg/m2 (24–28 kg/m2), after receiving appropriate informed
consent from relatives for multi-organ donation and for use in research. The human islet
characteristics are presented in Table 1.
4.2. Cell Differentiation
Before in vitro differentiation, the hiPSC lines were enriched with stage-specific em-
bryonic antigen-4 (SSEA4) positive cells by using magnetic beads (#130097855 MACS
Miltenyi Biotec). Three different hiPSC lines were differentiated in independent exper-
iments (differentiation rounds) according to a seven-stage protocol [24]. For this study,
we used 2D differentiation on Matrigel-coated 6-well plates as previously described by
us [33]. For each differentiation round, hiPSCs were cultivated in parallel dishes, with glass
coverslips added to each well. At stage 5 (pancreatic endocrine precursors), differentiating
cells were incubated in the respective differentiation media containing 3 different glucose
concentrations respectively (standard, 20 mM; elevated, 25 and 30 mM). At stage 7, the
cells were harvested for either global proteomics or immunofluorescence staining.
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Table 1. Checklist for reporting human islet preparations used in research. Table format adapted
from (Hart and Powers, 2019).
Islet Preparation 1 2 3
Mandatory Information
Donor age (years) 60 35 57
Donor sex
(male: M/female: F) M M F
Donor BMI (kg/m2) 27.8 25.2 24.2
Donor HbA1c or other measure of
blood glucose control (mmol/mol) 44 not assessed not assessed
Origin/source of islets ECIT a EDIT ECIT
Islet isolation centre Oslo Oslo Oslo
Donor history of diabetes? No No No
Recommended Information
Donor cause of death DBD b DBD DBD
Warm ischemia time (h) 02:00 03:00 02:25
Cold ischemia time (h) 05:03 09:48 07:07
Estimated purity (%) 53 50 70
Estimated viability (%) 90 95 90
Total culture time (h) c 72 72 72
Glucose-stimulated insulin secretion 2.3 2.2 4.3
Handpicked to purity? Yes Yes Yes
a—European Consortium for Islet Transplantation. b—Donation After Brain Death. c—Time of islet culture at the
isolation center, during shipment and at the receiving laboratory.
4.3. Cell Counting and Viability Measurements
For each experiment, the cell number and viability of each sample were measured
using NucleoCounter NC-200 (ChemoMetec, Allerod, Denmark) following the manu-
facturer’s instructions for Via1-Cassette (cat. no. 941-0012) with Reagent A100 (cat.
no. 910-0003) and B (cat. no. 910-0002).
4.4. H2O2 and DMSO Treatments
Differentiating hiPSC-derived cells (stage 7) were incubated in 20 µM hydrogen
peroxide fresh solution (H1009-100ML, Sigma, St. Louis, MO, USA) or 1% Dimethyl
Sulfoxide Solvent (DMSO D8418, Sigma, St. Louis, MO, USA) for 24 h and then harvested
and processed further for global proteomics or immunofluorescence staining. Cell viability
was above 85% in all conditions (Supplemental Figure S3).
4.5. Immunofluorescence Staining
Coverslips covered by differentiating hiPSC-derived cells were fixed in 2%
Paraformaldehyde (PFA) for 20 min at room temperature, followed by several washes
with phosphate-buffered saline (PBS). After blocking for 30 min at room temperature with
2% bovine serum albumin (BSA) in PBS, coverslips were incubated in primary antibody
overnight at 4 ◦C. The following primary antibodies were used: guinea pig anti-insulin
(1/500, A056401-2, Dako, Glostrup, Denmark) and rabbit anti-NRF2 (1/250, SAB4501984-
100UG, Sigma-Aldrich, St. Louis, MO, USA,). After brief washes in PBS, the coverslips
were incubated for 3 h at room temperature, in the dark, with the following secondary
antibodies: goat anti-guinea pig A488 and donkey anti-rabbit A647 (1/500, Molecular
Probes, Eugene, OR, USA). The nuclei were stained with DAPI (D1306, Molecular Probes,
Eugene, OR, USA). The coverslips were mounted on glass slides using Prolong Diamond
Antifade Mountant Media (P36970, Life technologies, Carlsbad, CA, USA) and images
were acquired using a Leica TCS SP5 STED CW confocal microscope (Leica Microsystems,
Wetzlar, Germany).
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4.6. Global Proteomics Analysis
Differentiating cells at stage 7 and following respective treatments were washed in
Dulbecco’s phosphate-buffered saline (DPBS, D8537, Sigma, St. Louis, MO, USA) and
harvested with TrypLE Select Enzyme (1X) (12563011, Thermo Fisher Scientific, Waltham,
MA, USA), followed by centrifugation. Cell pellets were lysed in a buffer of 8 M urea
(U1250, Sigma, St. Louis, MO, USA), 200 mM EPPS (3-[4-(2-Hydroxyethyl)piperazin-
1-yl]propane-1-sulfonic acid, E1894, Sigma, St. Louis, MO, USA) pH 8.5 and protease
inhibitors (Roche Complete with Ethylenediaminetetraacetic acid (EDTA), Roche Basel,
Switzerland, catalog number 11836153001) and sonicated for three rounds of 30 s at 30%
power. Human islets were lysed in 4% SDS buffer and boiled at 95 ◦C for 7 min on
a shaker, followed by sonication. The protein concentration was determined using a
bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA,
catalog number 23225). Dry aliquots containing an estimated amount of 100µg of proteins
were further processed using the Filter-Aided Sample Preparation method. Tandem Mass
Tag (TMT) 11-plex labeling, phase fractionation and LC-MS/MS analysis were performed
at the Taplin Facility at Harvard Medical School as previously described [48]. The mass
spectrometry proteomics data have been deposited to the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org, accessed on 11 February 2021) via the
PRIDE partner repository [49] with the dataset identifier PXD022177.
4.7. Proteomic Data Analysis
We analyzed the mass spectrometry data as earlier described [31,32]. Hierarchical
clustering on both entities and conditions using the squared Euclidian distance metric
and Ward’s linkage rule was performed with GeneSpring 14.9.1 GX software (Agilent
Technologies, Santa Clara, CA, USA). The pathway analyses were generated through the
use of the Ingenuity Pathway Analysis Program (IPA, QIAGEN Inc., Redwood City, CA,
USA) [50].
4.8. Statistical Analysis
Statistical analysis was performed using GraphPad Prism v8.4.3 (GraphPad Software
Inc., La Jolla, CA, USA). The unpaired two-tailed Student’s t-test was used for direct group
comparison. A one-way ANOVA with Tukey’s multiple corrections test was employed for
multiple group comparison. In both cases, a p-value of <0.05 was considered significant. In
figures, data are represented as mean ± SEM.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22073698/s1, Figure S1: IPA-generated global integration of all pathway analysis levels
characterizing the 25 mM glucose condition, Figure S2: IPA-generated global integration of all
pathway analysis levels characterizing the 30 mM glucose condition, Figure S3: Cell viability at the
end of stage 7 after DMSO and H2O2 treatments. Table S1: List of Differentially Expressed Proteins,
Table S2: Differentially Expressed Beta-cell Housekeeping Proteins.
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